Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party.

Ali Bazarbachi,Myriam Labopin,Tobias Gedde-Dahl,Peter Remenyi,Edouard Forcade,Nicolaus Kröger,Gerard Socié,Charles Craddock,Jean Henri Bourhis,Jurjen Versluis,Ibrahim Yakoub-Agha,Urpu Salmenniemi,Jean El-Cheikh,Gesine Bug,Jordi Esteve,Arnon Nagler,Fabio Ciceri,Mohamad Mohty

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览0

暂无评分

摘要

In AML patients with FLT3 ITDand wild-type NPM1, we noticed a significant decrease over time in the CIR and improvement of LFS and OS, likely reflecting the efficacy of FLT-3 inhibitors, including when used as post-transplant maintenance, in this high-risk setting. On the contrary, no significant change over time was noticed in outcomes of patients harboring a FLT3 and NPM1 mutation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要